Released on July 23, 2026, the most recent update to the American College of Cardiology (ACC) Expert Consensus Decision Pathway (EDCP) aims to redefine, recategorize, and reestablish treatment criteria for 

heart failure with preserved ejection fraction (HFpEF)

ACC Expert Consensus Decision Pathway Updates HFpEF Definition, Diagnosis & Treatment

Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026

, James Januzzi, MD, chief scientific officer and C. Michael Gibson Chair in Medicine at the Baim Institute for Clinical Research and Adolph Hutter Professor of Medicine at Harvard Medical School and co-author of the new guidelines, discusses their implications for HFpEF care moving forward.

“In the document, we acknowledge that heart failure with preserved ejection fraction is unique compared to other forms of heart failure, such as reduced ejection fraction,” Januzzi told 

. “We argued that clinicians need to take a very careful look at each patient on an individual level before deciding on specific therapeutic interventions.”

The original EDCP was published in 2023 – the present update shifts the definition of HFpEF from an individual cardiac condition to a multisystem syndrome driven by inflammatory pathways, visceral adiposity, and metabolic dysfunction. Additionally, the document highlights the distinct patient phenotypes prevalent in HFpEF and the individualized care required for these groups.

Among the key components of the new guideline is the critical importance of accurate diagnoses. Januzzi and colleagues provide a structured approach to evaluating patients, composed of 3 main steps: identifying patients with possible HFpEF based on characteristic signs and symptoms, assessing for HFpEF noncardiac and cardiac mimics, and implementing an HFpEF management plan incorporating comorbidities and nonpharmacologic management in addition to optimal medical therapy.

Additionally, the document provides an extensive list of potential cardiac and noncardiac mimics, recommending a diagnostic evaluation for each potential confounder to eliminate the possibility of HFpEF. These mimics can range from kidney disease, obesity, and pulmonary disease on the noncardiac side to aortic stenosis, ischemic heart disease, and cardiac amyloidosis.

Following diagnosis, the document offers a variety of guidelines regarding treatment and medication. Part of the impetus for the update was additional research conducted in the years following the 2023 release – this includes positive trial data supporting the use of SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor agonists, and incretin-based therapies like GLP-1 receptor agonists. The new guidelines recommend dosing and titration strategies for a wide range of medications in each of these classes.

However, Januzzi places a significant amount of importance on the diagnostic process itself. Given the long list of potential causes of HFpEF, he stresses that underdiagnosis is a prevalent threat as components of HFpEF are addressed individually rather than seeing the bigger picture.

“I would argue that underdiagnosis is probably more of a concern than overdiagnosis, given the fact that a person who has dyspnea, atrial fibrillation, and obesity, even before we start off with diagnostic testing, most likely has heart failure with preserved ejection fraction,” Januzzi said. “Clinicians therefore really need to have a high index of suspicion for the presence of heart failure because treatment in that situation can improve quality of life and functional capacity and can potentially reduce mortality and hospitalization risk.”

Editors’ Note: Januzzi reports disclosures with Abbott Laboratories, AbbVie, Inc., Eli Lilly, AstraZeneca Pharmaceuticals, Jana Care, Siemens, and others.

Kittleson MM, Panjrath GS, Bates K, et al. Management of heart failure with preserved ejection fraction: 2026 ACC expert consensus decision pathway. JACC. 2026;88(15):1817-1846. 

American College of Cardiology. Updated ACC Expert Consensus Decision Pathway Addresses Management of HFpEF. 

. July 23, 2026. Accessed October 14, 2026. 

https://www.acc.org/latest-in-cardiology/journal-scans/2026/07/22/17/25/updated-acc-ecdp-addresses-management-of-hfpef

Videos

James Januzzi, MD, discusses the recently released guideline update and how it should change clinicians’ priorities in addressing and preempting HFpEF.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Kyle Staller, MD, MPH, is a gastroenterologist and the director of the Gastrointestinal Motility Laboratory at Mass General.

Adults with irritable bowel syndrome with constipation (IBS-C) used fewer gastrointestinal (GI) health care resources in the year after starting tenapanor (Ibsrela). The data were presented at the 

American College of Gastroenterology (ACG)

The retrospective analysis included 470 patients from a national 

 practice. Median GI-related health care resource utilization (HCRU) fell from 4.5 visits in the year before tenapanor initiation to 3.0 visits in the year after 

 <.001).² Significant reductions were also seen among patients who had previously tried ≥1 IBS-C medication.

“We know that the vast majority of patients with IBS don’t necessarily present to a gastroenterologist, but among those that do, they really have a high degree of healthcare resource utilization, and I think we wonder: is that really a surrogate for dissatisfaction? That perhaps these patients are utilizing resources because they’re not happy with the current plan of care,” Kyle Staller, MD, MPH, director of the Gastrointestinal Motility Laboratory at Massachusetts General Hospital and first author of the analysis, said in an interview with 

Tenapanor Linked to Lower IBS-C Care Use, With Kyle Staller, MD, MPH

How Tenapanor’s Mechanism Differs From IBS-C Secretagogues

Most existing IBS-C therapies are secretagogues. They actively secrete ions into the intestinal lumen, and water follows to produce bowel movements.

Tenapanor is a locally acting inhibitor of sodium/hydrogen exchanger 3 (NHE3). It reduces sodium absorption in the small intestine and colon, which keeps water in the lumen and softens stool.² Staller described the drug as a retainagogue rather than a secretagogue.

The different mechanism and the drug’s newness on the market prompted the investigators’ question: would patients starting tenapanor de novo show a change in HCRU?

Median GI Visits Fell From 4.5 to 3.0 After Tenapanor Initiation

Eligible patients had ≥1 year of data before and after starting tenapanor and ≥1 outpatient visit, according to Staller. The analysis drew on electronic health records rather than billing codes alone.

The interquartile range for GI-related HCRU narrowed from 2 to 9 before initiation to 1 to 6 after.² The reductions held in subgroups regardless of body mass index or comorbidity burden.

Staller said the decline was most notable in office visits. He said this could reflect patients who feel more satisfied and no longer return to report ongoing symptoms.

Before and After Design Limits Causal Conclusions on Tenapanor

“I’m very confident that that reduction is real. I’m not sure that we can definitively say that that reduction is because they started tenapanor, but I think you do have to wonder, right? The patient starts tenapanor, and that reduction is very clear,” Staller said.

The analysis compared each patient’s use before and after initiation without a separate comparison group. Staller noted that factors other than tenapanor could contribute to the decline.

He also pointed to the data source as a strength. Patients came from large community GI practices across the country rather than the academic centers that typically supply this type of research.

Editor's note: Staller reports disclosures with AbbVie, Ardelyx, Gemelli, Salix, and Takeda.

Staller K, Fossa A, O’Byrne M, Scott LL. Health care resource utilization decreases among patients with constipation predominant irritable bowel syndrome following initiation of tenapanor: a real-world analysis. Poster P3082. Presented at: ACG 2026 Annual Scientific Meeting; October 12, 2026.

Ardelyx presents real-world data at ACG 2026 showing reduced healthcare resource utilization following IBSRELA initiation in adults with IBS-C. News release. Ardelyx. October 12, 2026.

A real world analysis of 470 patients presented at ACG 2026 found median GI visits fell from 4.5 to 3.0 in the year after initiation

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

A combination of measurements of transthyretin stabilization (sTTR) with a later myocardial stress marker like NT-proBNP creates a biomarker ratio that may predict clinical outcomes in patients with 

transthyretin amyloid cardiomyopathy (ATTR-CM)

Ratio of sTTR and NT-proBNP Change May Predict Treatment Results in ATTR-CM

These data, from an analysis of the ATTRibute-CM trial, were presented at the 

 in Phoenix, Arizona, by James Januzzi, MD, chief scientific officer and C. Michael Gibson Chair in Medicine at the Baim Institute for Clinical Research and Adolph Hutter Professor of Medicine at Harvard Medical School.

“Acoramidis is an oral therapy used to stabilize transthyretin, and it’s known that treatment with acoramidis leads to an early increase in transthyretin, and it’s known that treatment leads to an early increase in transthyretin concentrations that are actually favorable,” Januzzi told 

 in an exclusive interview. “We hypothesized that the increase in transthyretin might predict changes in NT-proBNP later after treatment.”

ATTRibute-CM was a phase 3, randomized, double-blind, placebo-controlled study comparing acoramidis to placebo in ATTR-CM. Patients were eligible for inclusion if they had either wild-type or variant ATTR-CM and a history of 

, among other criteria. Patients with acute myocardial infarction, hemodynamic instability, or primary light chain amyloidosis, among other criteria, were excluded.

A total of 632 patients were enrolled in the study and randomly assigned in a 2:1 ratio to either acoramidis hydrochloride at 800 mg twice daily or matching placebo. Over 30 months, investigators evaluated a 4-step hierarchical analysis of death from any cause, cardiovascular-related hospitalization, change in NT-proBNP from baseline, and change in 6-minute walk distance from baseline.

This primary analysis ultimately favored acoramidis, with a corresponding win ratio of 1.8 (95% CI, 1.4 to 2.2) and 63.7% of pairwise comparisons favoring acoramidis. All-cause mortality and cardiovascular hospitalization contributed >50% of the wins and losses to the win ratio, while NT-proBNP pairwise comparisons yielded the highest ratio of wins to losses.

For the present post-hoc evaluation, Januzzi and colleagues used observed biomarker data from the intention-to-treat population to conduct time-to-event analyses. Samples were collected from this population at baseline, day (D)28, and every 3 months (M) from then on; sTTR and NT-proBNP were measured centrally. The team constructed an integrated biomarker ratio of log2-transformed D28 sTTR/log2-transformed M12 NT-proBNP from these data.

Of the 632 intention-to-treat patients, 587 had baseline and M30 biomarker values. The mean age among these patients was 77 +/- standard deviation (SD) 7 years. 90% of patients had wild-type ATTR-CM, 72% were New York Heart Association functional class 2, and 59% were National Amyloidosis Centre stage 1. Median sTTR and NT-proBNP were 23 mg/dL and 2324 ng/L, respectively.

Early changes in sTTR preceded later changes in NT-proBNP, with the former increasing rapidly by D28 and remaining elevated with acoramidis compared to little change with placebo. NT-proBNP increased to a lesser extent with acoramidis versus placebo. These changes correlated weakly when measured at the same time point, but correlations between D28 sTTR change and later NT-proBNP change were stronger.

This ratio was also strongly associated with all-cause mortality and cardiovascular hospitalization risks in M12 landmark analyses. Januzzi and colleagues found that each 0.1-unit increase in the ratio was associated with a 63% lower adjusted risk of these endpoints (HR, 0.37; 95% CI, 0.24 to 0.58; 

 <.001). The team observed a continuous biomarker-risk gradient, and mediation analyses revealed that the effect of acoramidis treatment on all-cause mortality and cardiovascular hospitalization was associated with an HR of 0.66.

Ultimately, Januzzi and colleagues concluded that, while these data may reflect an effective and accurate predictor of cardiovascular risk in ATTR-CM, several potential study limitations may hamper the ratio’s accuracy in real-world practice. To this end, they determined that further research is necessary to fully validate the biological pathway linking these targets with long-term clinical benefit with acoramidis.

“I think the most important thing that we can say is that biomarker testing really can be extremely informative, not just about the presence and severity of ATTR-CM, but also with respect to its response to treatment,” Januzzi said. “We need more data about the role of biomarkers to help people manage transthyretin cardiomyopathy, but I would argue that the future is very bright in this regard.”

Myhre P, Murtagh G, Gaggin H, et al. Implications of Serum Transthyretin to NT-proBNP Ratio in Transthyretin Amyloid Cardiomyopathy: Insights From ATTRibute-CM. 

https://doi.org/10.1016/j.jchf.2026.103493

Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of ACORAMIDIS in transthyretin amyloid cardiomyopathy. New England Journal of Medicine. 2024;390(2):132-142. 

Eidos Therapeutics. Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM). ClinicalTrials.gov Identifier: NCT03860935. Updated June 27, 2026. Accessed October 14, 2026. 

https://clinicaltrials.gov/study/NCT03860935

James Januzzi, MD, discusses his post-hoc analysis of the ATTRibute-CM study, revealing a potential predictive ratio between these 2 measurements.

Cardiomyopathy

Aasma Shaukat, MD, MPH, is the Robert M. and Mary H. Glickman Professor of Medicine; Professor of Population Health; Director, GI Outcomes Research at
NYU Langone Health.

An updated version of the SimpleScreen CRC blood test detected advanced precancerous lesions (APLs) with 18.2% sensitivity, up from 13.7% with the previous version, while maintaining 80.4% sensitivity for 

. The late-breaking results come from a clinical validation study presented at the 

American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

SimpleScreen CRC, developed by Freenome, received US Food and Drug Administration (FDA) approval based on the PREEMPT CRC study. In that study, the original test achieved 79.2% CRC sensitivity, but its 12.5% APL sensitivity missed the prespecified acceptance criterion.

Aasma Shaukat, MD, MPH, of NYU Grossman School of Medicine, told 

 APL detection is central to CRC prevention, and current blood tests fall short of stool-based tests on this measure.

Can Blood Tests Catch Precancerous Lesions? Updated CRC Screening Test

“It’s really important that we see an improvement in that advanced precursor lesion because in their current form they don’t confer the same amount of protection or prevention as tests that have higher detection of advanced precursor lesions,” she explained.

Assay and Algorithm Updates to the SimpleScreen CRC Blood Test

Shaukat said the updated version incorporates two changes: assay modifications to improve the signal-to-noise ratio, and algorithm refinements trained on prior results to detect circulating tumor DNA at the base-pair level. Validation drew on PREEMPT CRC, which enrolled 48,995 average-risk adults aged 45 to 85 years undergoing screening colonoscopy.

The validation cohort included all previously untested CRC (n = 26) and APL (n = 1142) samples. As prespecified and aligned with the FDA, investigators added previously tested samples with sufficient volume: 70 CRCs, 517 randomly selected APLs, and 70 additional APLs with high-grade dysplasia (HGD).

The evaluable cohort comprised 9001 participants, including 89 with CRC, 1570 with APLs, and 7342 without advanced neoplasia, with a mean age of 60.0 years. The positivity threshold targeted 90% specificity among participants with no colonoscopic findings, and sensitivity estimates were adjusted to the US Census age-sex distribution.

Updated Blood Test Sensitivity for CRC and Advanced Precancerous Lesions

The updated test achieved CRC sensitivity of 80.4% (95% CI, 70.2%-87.7%).¹ Sensitivity was 52.0% for stage I cancers (T1, 39.9%; T2, 81.2%), 100% for stage II, 97.3% for stage III, and 100% for stage IV. The stage I estimate was numerically lower than with the previous version, with overlapping confidence intervals.

APL sensitivity was significantly higher with the updated test (18.2%; 95% CI, 16.3%-20.4%) than with the previous version (13.7%; 95% CI, 12.4%-15.0%), with improvements across APL subtypes.¹ Sensitivity for APLs with HGD was 41.9% (95% CI, 34.0%-50.3%) among 157 evaluable cases.

Specificity was 90.0% (95% CI, 89.0%-91.0%) among participants with no colonoscopic findings and 89.7% (95% CI, 89.0%-90.4%) among those without advanced neoplasia.

Modeled Impact and Role of Blood-Based CRC Screening

In a validated microsimulation model of screening every 3 years from ages 45 to 75, the updated test was projected to prevent 426 more CRC cases (9.5%) and 143 more CRC deaths (9.5%) per 100,000 adults, and to add 1582 life-years (7.7%), compared with the previous version.

Shaukat said blood tests are better than no screening but currently inferior to colonoscopy and stool-based testing, and she still prefers patients complete one of those options. She expects blood test sensitivity for APLs to reach parity with stool tests over time. She added the goal is to reach patients who decline or cannot complete colonoscopy, with follow-up colonoscopy after any abnormal result.

“So we’re looking for that addition and not substitution, which is obviously a big concern,” said Shaukat.

Editors’ note: Shaukat reports relevant disclosures with Freenome, Geneoscopy, and UniversalDx.

Shaukat A, Burke CA, Gupta S, et al. Improved sensitivity for advanced precancerous lesions demonstrated in clinical validation of an updated colorectal cancer screening blood test in an average-risk population. Presented at: American College of Gastroenterology 2026 Annual Scientific Meeting; October 9-14, 2026; Nashville, TN.

Shaukat A, Burke CA, Chan AT, et al. Clinical validation of a circulating tumor DNA-based blood test to screen for colorectal cancer. JAMA. 2025;334(1):56-63. doi:10.1001/jama.2025.7515

Aasma Shaukat, MD, MPH, discusses an updated SimpleScreen CRC blood test with 18.2% sensitivity for advanced precancerous lesions, up from 13.7%.

Updated SimpleScreen CRC Blood Test Improves Precancerous Lesion Detection

Manish Ramesh, MD, PhD, chief of the division of allergy and immunology at Montefiore Einstein

, Manish Ramesh, MD, PhD, chief of the division of allergy & immunology at Albert Einstein College of Medicine, cited early allergen introduction, oral immunotherapy (OIT), and omalizumab (Xolair) as key advances in 

Ramesh described food allergy as the first chronic immune illness clinicians can prevent, not only treat. He linked the 

first population-level reduction in peanut allergy incidence to the early introduction strategy

“You can’t prevent lupus, you can’t prevent asthma, but you can prevent food allergies,” Ramesh said. “Early introduction of foods in very young children can help prevent the development of food allergies in the future.”

Food Allergy Prevention and Treatment Advances, With Manish Ramesh, MD, PhD

Early Allergen Introduction and Declining Peanut Allergy Incidence

Peanut Allergy Rates Plummet 10 Years After AAP Early Introduction Guideline


Investigators and allergists discuss real-world declines in peanut and food allergy following the 2015 and 2017 early introduction guidelines.

Viaskin Peanut Patch FAQ: Where It Fits Beside Omalizumab and OIT


A clinician FAQ on DBV Technologies’ BLA for the patch in children aged 4 to 7 years, and where it would sit beside omalizumab and office-based OIT.

Anaphylm Is Back at the FDA: A Clinician FAQ on Needle-Free Epinephrine


What changed in Aquestive’s resubmission of its sublingual epinephrine film after an FDA Complete Response Letter focused on usability, not efficacy.

Primary care data from a multistate pediatric network support the population-level shift Ramesh described. Stanislaw J. Gabryszewski and colleagues compared health records of children aged 0 to 3 years before and after the 2015 early peanut introduction guidelines and 2017 addendum guidelines.¹

The cumulative incidence of peanut IgE-mediated food allergy fell from 0.79% to 0.53% after the initial guidelines (hazard ratio [HR], 0.65; 95% CI, 0.55-0.77; 

 <.0001).¹ Following the addendum guidelines, incidence fell further to 0.45% (HR, 0.55; 95% CI, 0.46-0.66; 

 <.0001).¹ Rates of any IgE-mediated food allergy also declined, from 1.46% to 1.02% (HR, 0.69; 95% CI, 0.61-0.78).¹

Ramesh said the timing of exposure matters beyond foods alone. Early childhood exposures, including environmental exposures, appear central to whether allergic disease develops, he noted.

Oral Immunotherapy and Omalizumab for Food Allergy

Oral immunotherapy (OIT) remains the most common treatment option, according to Ramesh.

Ramesh also highlighted omalizumab as the first biologic approved for food allergy in both children and adults.

 He said the anti-IgE antibody reduces reaction severity and raises the amount of food needed to trigger a reaction.

Among 177 children and adolescents aged 1 to 17 years in a randomized, placebo-controlled trial, 67% receiving omalizumab tolerated a single dose of ≥ 600 mg of peanut protein without dose-limiting symptoms.

 This compared with 7% of participants receiving placebo (

 <.001). Results for cashew (41% vs 3%), milk (66% vs 10%), and egg (67% vs 0%) were consistent with the primary end point, and safety end points did not differ between groups aside from more injection-site reactions with omalizumab.

 Ramesh said both are expected to become available for clinical use soon.

How Genetics Is Reshaping Allergic Disease Phenotyping

Asked how understanding of allergic disease has changed in the past decade, Ramesh pointed first to immune mechanisms. Recognition of distinct phenotypes in asthma, chronic urticaria, and atopic dermatitis has shifted management toward immune mechanism-based phenotyping, he said.

Ramesh also cited hereditary alpha-tryptasemia, defined by extra copies of the tryptase gene, as a readily screened genetic trait associated with increased anaphylaxis risk.

Epigenetic changes, which are heritable but arise far faster than mutations, account for much of the generation-to-generation rise in atopy, according to Ramesh.

Monogenic disorders have offered further insight, as genetic testing has revealed single-gene mutations in some patients presenting with severe allergic disease and immune dysfunction. Unlike classic immunodeficiencies, where a mutation confers susceptibility to infection, these mutations alter immune behavior itself.

“In this case, the alterations in the genes change how your immune system behaves and, in some ways increases allergic disease, similar to what we would see with autoimmune disease,” said Ramesh.

Ramesh said these insights into immune mechanisms are now driving development of new biologics and small molecules for chronic allergic disease. He noted these agents already support management of properly phenotyped patients with asthma, atopic dermatitis, and chronic urticaria.

Gabryszewski SJ, Dudley J, Faerber JA, et al. Guidelines for early food introduction and patterns of food allergy. 

Gabryszewski S, Gupta R, Hernandez-Trujillo V, et al. Peanut Allergy Rates Plummet 10 Years After AAP Early Introduction Guidelines. HCPLive. Published October 30, 2025. Accessed October 14, 2026. 

https://www.hcplive.com/view/peanut-allergy-rates-plummet-10-years-aap-early-introduction-guidelines

Smith T. FDA Approves Omalizumab as First Treatment of 1 or More Food Allergies for Children, Adults. HCPLive. Published February 16, 2024. Accessed October 14, 2026. 

https://www.hcplive.com/view/fda-approves-omalozumab-first-treatment-of-1-or-more-food-allergies-for-children-adults

Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the treatment of multiple food allergies. 

Larenas-Linnemann D. Sublingual Immunotherapy for Allergy in 2026, With Désirée Larenas-Linnemann, MD. HCPLive. Published March 9, 2026. Accessed October 14, 2026. 

https://www.hcplive.com/view/sublingual-immunotherapy-allergy-2026-d-sir-e-larenas-linnemann-md

Derman C. Viaskin Peanut Patch FAQ: Where It Fits Beside Omalizumab and OIT. HCPLive. Published October 8, 2026. Accessed October 14, 2026. 

https://www.hcplive.com/view/viaskin-peanut-patch-faq-omalizumab-oit

Korošec P, Lyons JJ, Svetina M, et al. Hereditary α-tryptasemia is Associated With Anaphylaxis to Antibiotics and Monoclonal Antibodies. 

Ramesh outlines early food introduction, oral immunotherapy, omalizumab, and genetic insights shaping how allergists treat allergic disease.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Strategic Alliance Partnership

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Articles

Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.

Acne

The HCPLive acne page is a resource for medical news and expert insights on dermatological disease. This page features expert-led coverage, articles, videos, and research on the therapies and development of treatments for chronic acne, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

In mice, liraglutide reduced steatosis through PPARα without needing iNKT cells, pointing to a possible GLP-1 RA plus PPARα combination.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

How GLP-1 RAs May Reduce Liver Fat in MASLD, With Takashi Miki, MD, PhD

Evan Dellon, MD, MPH, is a professor in the division of gastroenterology and hepatology and director of the Center for Esophageal Diseases and Swallowing at UNC School of Medicine.

Evan Dellon, MD, discusses phase 3 CROSSING data in which tezepelumab improved histology, dysphagia, and endoscopic findings vs placebo in EoE.

Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis

In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.

Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial 

Martin Maron, MD, is the medical director of the Lahey Hospital & Medical Center.

Martin Maron, MD, discusses the results of his responder analysis of the trial, presented at HFSA 2026, and the implications for aficamten’s path towards approval.

ACACIA-HCM Analysis Underscores Aficamten’s Effect on nHCM Outcome Measures

Montefiore allergist outlines updated guidance on home monitoring after epinephrine and why immunotherapy remains underused in allergic rhinitis.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Seasonal Allergy

Anaphylaxis, Allergic Rhinitis Care Gaps, With Manish Ramesh, MD, PhD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

David T. Rubin, MD is a professor of medicine at the University of Chicago, director of the Inflammatory Bowel Disease Center, and chair of the International Organization for the Study of IBD (IOIBD).

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

Latest News

ACC Expert Consensus Decision Pathway Updates HFpEF Definition, Diagnosis & Treatment

Tenapanor Linked to Lower IBS-C Care Use, With Kyle Staller, MD, MPH

Ratio of sTTR and NT-proBNP Change May Predict Treatment Results in ATTR-CM

Updated SimpleScreen CRC Blood Test Improves Precancerous Lesion Detection

Food Allergy Prevention and Treatment Advances, With Manish Ramesh, MD, PhD